F or decades, the serial measurement of coronary plaque volume with use of intravascular ultrasound (IVUS) has enabled drug efficacy in coronary atherosclerotic regression to be evaluated. Because it provides high-resolution views and validation of coronary plaque, numerous investigators have used IVUS to evaluate the efficacy of statins in inhibiting coronary plaque progression, changes in plaque composition, and stabilization of plaque vulnerability. [1] [2] [3] [4] [5] [6] [7] In addition, IVUS findings have characterized the natural history of coronary atherosclerosis in patients with acute coronary syndrome, in association with cardiac events. 8 However, invasiveness, high cost, and associated morbidity make its routine use impractical, particularly in asymptomatic patients.
Coronary computed tomographic angiography (CCTA)-a robust, noninvasive means of evaluating the presence, extent, and severity of coronary artery disease (CAD) 9 -correlates well with IVUS in determining coronary plaque characteristics, 10 stenosis severity, 11 and volume. [12] [13] [14] [15] The diagnostic capabilities of CCTA have been useful in defining the natural history of coronary plaque and its changes over time during drug therapy. [16] [17] [18] [19] However, in terms of investigating serial changes in coronary plaque, IVUS and CCTA have not been directly compared. We investigated whether serial changes in total coronary plaque volume (TPV), measured by using CCTA, are associated with serial changes in segmental coronary plaque volume (SPV), measured by using IVUS.
Patients and Methods
We prospectively enrolled 11 consecutive patients (mean age, 56.3 ± 5 yr; 6 men) with known or suspected CAD. All underwent serial invasive coronary angiography at our institution from February 2006 through August 2013 via grayscale IVUS and noninvasive CCTA, at baseline and from 1 to 2 years later (mean durations, 705 ± 86 d for IVUS and 698 ± 106 d for CCTA; P >0.05). Intravascular ultrasound and CCTA were performed within a mean of 31 ± 39 days. No patient underwent coronary intervention or had a clinical cardiovascular event (hospitalization for angina, myocardial infarction, or stroke) between the baseline and follow-up examinations. We excluded patients who had renal impairment (serum creatinine level, >1.4 mg/dL), history of coronary artery bypass grafting, or >180 days between CCTA and IVUS examinations. This study was approved by our Institutional Review Board, and all patients gave written informed consent.
All patients underwent invasive coronary angiography by means of IVUS on an iLab Ultrasound Imaging System (Boston Scientific Corporation). An automated pullback at 0.5 mm/s was performed on the target vessel. The same vessel was evaluated at baseline and follow-up. No patient had complications. Experienced readers studied the target vessels for the presence and volume of coronary plaque by using semiautomated QIvus ® plaque-analysis software (Medis Medical Imaging Systems). The software automatically traced contours of the luminal and vessel walls inside the IVUS pullback stack. When necessary, we manually modified the lines by using cross-sectional images (Fig. 1 ).
We performed CCTA by using a 64-slice Lightspeed VCT scanner (GE Healthcare). Scanning values were typically 70% to 80% of the R-R interval for prospective electrocardiogram-triggering studies and 35% to 80% for retrospective studies; collimation, 64 × 0.625 mm; tube voltage, 100 to 120 kV; and tube current, 350 to 780 mA. To attain target heart rates of <60 beats/ min before scanning, patients were given oral or intravenous β-blockers, and, immediately before the study, sublingual nitroglycerin or nitroglycerin spray (0.4-0.8 mg). Experienced readers used QAngioCT ® Research Edition version 2.0.5 (Medis), a semiautomated plaqueanalysis software program, to evaluate CCTAs for the presence and volume of coronary plaques. Detected plaques were assigned locations in accordance with a modified 18-segment American Heart Association coronary tree model. 20 The QAngioCT software automatically extracted centerlines, detected the inner luminal and vessel wall contours from the ostium to the distal end of each artery, and produced straightened multiplanar reformatted images (Fig. 2) . When necessary, we manually modified the contours. Window level and width were set at 740 and 220 Hounsfield units, respectively. Only segments ≥1.5 mm in diameter and of sufficient image quality were evaluated; those with stents or artifact were excluded.
Coronary Plaque Volume Calculations
At baseline and follow-up, TPV (measured by CCTA) and SPV (measured by IVUS) were derived as follows: vessel volume -luminal volume (mm 3 ). The percentages of TPV or SPV were then calculated as follows: [(TPV or SPV/total vessel volumes) × 100]. Change in percentage was defined as the difference between baseline and follow-up values. Normalized plaque volume was calculated as follows: [(TPV or SPV/total or segmental length of coronary artery) × mean total or segmental length of all studies].
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Statistical Analysis
All analyses of CCTA variables were performed independently and with blinding to the IVUS measurements. A paired t test was used to compare variables from CCTA and IVUS at baseline and follow-up for normally distributed variables, and the Kruskal-Wallis test for nonparametrically distributed variables. Agreement between 2 observers in plaque measurements by CCTA and IVUS was evaluated with use of an intraclass correlation coefficient. The Pearson correlation coefficient was calculated to evaluate plaque volume and serial changes between IVUS and CCTA. P values <0.05 were considered statistically significant. Statistical analyses were performed with use of SAS version 9.3 (SAS Institute Inc.). Table I shows the baseline characteristics of the study population. All patients were taking antihypertensive medications, most took statins, and nearly half took medication for diabetes mellitus. Table II shows the variables measured on CCTA and IVUS at baseline and follow-up. There were no differences in total vessel, luminal, or plaque volumes. On CCTA, the changes in TPV percentage (0.7% ± 6.2% [median, 0.4%]) and normalized plaque volume (-4.4 ± 26.7 mm 3 [median, 3.7 mm 3 ]) were relatively small. Similar minimal changes on IVUS were found: SPV percentage, -0.2% ± 4.5% (median, -0.3%); and normalized plaque volume, 0.1 ± 6.2 mm 3 (median, 0.4 mm 3 ).
Results
We evaluated 93 vascular segments on CCTA (total from baseline and follow-up, 186) and these 11 segments on IVUS (total, 22): left anterior descending (Fig. 3A) . When we compared coronary plaque volume by using normalized plaque volume, we found no significant relationship between CCTA and IVUS (r=0.21; P=0.34) (Fig. 3B) . On per-patient analysis, performed to determine whether total plaque change on CCTA was associated with segmental plaque change on IVUS, we found strongly correlated serial changes between TPV-percentage change on CCTA and SPVpercentage change for IVUS (r=0.62; P=0.04) (Fig.  4A ). An even stronger correlation existed between the changes in normalized coronary plaque volume (r=0.82; P=0.002) (Fig. 4B) .
As was previously reported 21 in regard to interobserver variability of measurements when using CCTA, we too observed moderate correlations in TPV measurement between 2 observers (correlation coefficient, 0.94; 95% CI, 0.80-0.98). When we examined interobserver variability for coronary artery plaque measurements on IVUS among 5 randomly selected cases (10 vessels) in blinded fashion, we observed a moderate variability for SPV (correlation coefficient, 0.52; 95% CI, -0.12 to 0.86).
Discussion
To our knowledge, this is the first direct comparison of CCTA and IVUS measurements of plaque changes over time. We could not use IVUS to measure total plaque burden, so we compared SPV to TPV on CCTA and found only modest correlations. However, we found significant correlation between SPV and TPV.
Papadopoulou and colleagues 19 reported the potential usefulness of CCTA in evaluating the natural history of coronary atherosclerosis. They measured TPV and changes in plaque over 39 months in 32 patients with acute coronary syndromes who had undergone coronary intervention. Ito and associates 22 also studied coronary plaque progression in 148 patients, using serial CCTA (median scan interval, 12 mo). However, neither group directly compared CCTA and IVUS findings.
The results of our study strengthen those of Papadopoulou's group 19 and also indicate that TPV change on CCTA is associated with SPV change on IVUS. Coronary artery disease is systemic, so partial plaque change may be associated with systemic atherosclerotic change. Although our patient numbers are small, our findings support this concept. Because CCTA has lower image resolution than IVUS, one might overestimate plaque volume on CCTA. In particular, calcified plaque from blooming artifact can cause small, insignificant differences between CCTA and IVUS findings. 13, 14 Despite this, distortion of image quality is similar across serial scans. Advantageously, CCTA can produce 3-dimensional coronary artery models, and change in total coronary plaque is more practical than change in SPV for evaluating atherosclerotic progression. Therefore, we also evaluated normalized plaque volume and changes. 19, 23 We calculated volume percentage by dividing all measured plaque volume by the total measured vessel volume per patient. This might cause errors in calculations, even when the same patients are evaluated at baseline and follow-up. On CCTA images, vessel volume-in particular, luminal volume-can be affected by image quality because of the timing or dosing of nitroglycerin or contrast agents. Because the change in plaque volume over time was relatively small during our observation period, this error potentially af- fects the results of our serial CCTA study. Moreover, during serial measurements, total coronary segment length as evaluated by CCTA or IVUS is important when determining TPV. 23 In this regard, normalized plaque volume, which was calculated not by vessel volume but by the mean length for all studies, may be more reliable in evaluating plaque changes in serial CCTA study. This underlying mechanism may explain why the change in normalized plaque volume on CCTA was more strongly associated than that on IVUS in the current study.
Determination of plaque progression might help when selecting patients who would benefit from additional medical intervention or modification of risk factors, or in stratifying further risk. 22, [24] [25] [26] 
Study Limitations
This was a single-center study. The small sample (11 patients) might have affected some results, such as interobserver variability of plaque volume on IVUS. The plaque changes measured on CCTA and IVUS over time were relatively small, and the difference in plaque change between these modes might be greater in a larger cohort.
Serial CCTA exposes patients to additional radiation; however, newer CCTA technology enables lower radiation exposure and acceptable image quality. 27 Moreover, current high-pitch CCTA models might emit radiation doses within <1 mSv for CCTA, 28 considerably below the 5-mSv level needed for invasive angiography. 29 During investigation of serial changes in plaque volume by examining calcif ied or noncalcif ied plaque (including low-attenuation plaque), fibrous or fibrousfatty plaques are clinically important. Specifically, noncalcified plaque is associated with faster progression of CAD than is calcified plaque, 16 and its prevalence might inf luence the occurrence of future cardiovascular events. 30 We did not examine plaque characteristics on virtual-histology IVUS, so we could not examine the relationship of plaque-type progression between CCTA and IVUS. Advanced CCTA software can now identify plaque characteristics equally as well as can IVUS 31 or histology, 32 so future studies are warranted to evaluate the correlation of serial change of each plaque characteristic's volume between CCTA and IVUS.
Conclusion
We found a strong, significant correlation of plaque changes between CCTA and IVUS. This suggests that using CCTA-a less invasive imaging method than IVUS-is advantageous in evaluating atherosclerotic progression in patients with CAD; however, larger studies are warranted for validation. 
